The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
Featured:
Gilles SallesDuring the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
Salles begins by reminding us of the POLARIX trial and discusses studies investigating further tools and combination therapies like POLARIS and POLARGO. Salles explains why moving polatuzumab vedotin to frontline therapy will mean it is less likely to be used for R/R patients. Finally, Salles highlights the advancements we have seen in the field and predicts further studies that will explore treatments utilizing therapies like bispecific antibodies.